0001638234-17-000002.txt : 20171004 0001638234-17-000002.hdr.sgml : 20171004 20171004135834 ACCESSION NUMBER: 0001638234-17-000002 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20171004 DATE AS OF CHANGE: 20171004 EFFECTIVENESS DATE: 20171004 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Acer Therapeutics Inc. CENTRAL INDEX KEY: 0001638234 IRS NUMBER: 320426967 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-295986 FILM NUMBER: 171121141 BUSINESS ADDRESS: STREET 1: 222 THIRD STREET, SUITE 2240 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-922-3600 MAIL ADDRESS: STREET 1: 222 THIRD STREET, SUITE 2240 CITY: CAMBRIDGE STATE: MA ZIP: 02142 D 1 primary_doc.xml X0708 D LIVE 0001638234 Acer Therapeutics Inc. 222 THIRD STREET, SUITE 2240 CAMBRIDGE MA MASSACHUSETTS 02142 844-902-6100 DELAWARE None None Corporation true 2013 Christopher Schelling c/o Acer Therapeutics Inc. 222 Third Street, Suite 2240 Cambridge MA MASSACHUSETTS 02142 Executive Officer Director Stephen Aselage c/o Acer Therapeutics Inc. 222 Third Street, Suite 2240 Cambridge MA MASSACHUSETTS 02142 Director John Dunn c/o Acer Therapeutics Inc. 222 Third Street, Suite 2240 Cambridge MA MASSACHUSETTS 02142 Director Luc Marengere c/o Acer Therapeutics Inc. 222 Third Street, Suite 2240 Cambridge MA MASSACHUSETTS 02142 Director Hubert Birner c/o Acer Therapeutics Inc. 222 Third Street, Suite 2240 Cambridge MA MASSACHUSETTS 02142 Director Harry S. Palmin c/o Acer Therapeutics Inc. 222 Third Street, Suite 2240 Cambridge MA MASSACHUSETTS 02142 Executive Officer Robert Steiner c/o Acer Therapeutics Inc. 222 Third Street, Suite 2240 Cambridge MA MASSACHUSETTS 02142 Executive Officer Pharmaceuticals Decline to Disclose 06b false 2017-09-19 false true false 0 Piper Jaffray & Co. 665 None None 345 Park Avenue 12th Floor New York NY NEW YORK 10154 All States false 15674384 15674384 0 false 10 1097026 true 67495 true The sales commission and finders' fees reflect amounts described in an invoice provided by Piper Jaffray & Co. The total amount payable remains in dispute. 948000 true The Issuer expects to use approximately $948,000 of the proceeds for salary and other compensation to the Issuer's executive officers and directors. false Acer Therapeutics Inc. /s/ Harry S. Palmin Harry S. Palmin Chief Financial Officer 2017-10-04